Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High-Grade Neuroendocrine Cancers
Clinical trial NCT04802174 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04802174
- Sponsor
- National Cancer Institute (NCI)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-06-01
- Primary completion
- 2025-12-17
- Enrollment
- 37
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.